# A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Source: https://onco.cc/trials/nct06634589/  
OnCo record `nct06634589` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab in non-Hodgkin lymphoma, run by BeOne Medicines, now recruiting.

## Summary

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT06634589 by BeOne Medicines, with 80 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-12-02. Interventions recorded: Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06634589
- Phase: 1/2
- Setting: A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
- Sponsor: BeOne Medicines
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06634589: https://clinicaltrials.gov/study/NCT06634589

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Glofitamab](https://onco.cc/drugs/glofitamab/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct06634589.json